Orthocell Collaborates with Johnson & Johnson Innovation

By Julie A. Vetalice

Orthocell entered into a research collaboration agreement with DePuy Synthes Products for its Ortho-ATI® stem cell treatment for tendon and ligament regeneration. A joint multi-center study is slated for 1Q17 in Australia.

The collaboration was facilitated by Johnson & Johnson Innovation.

Ortho-ATI Autologous Tenocyte Implantation is a non-surgical approach to treat chronic, treatment-resistant tendon injuries that have a significant negative effect on daily living activities.

In previous studies, Ortho-ATI has been shown to be a cost effective, durable, non-surgical solution for hard-to-treat tendon injuries. The product is available in Australia and New Zealand for patients who have failed conservative treatment options.

Sources: Orthocell Limited; ORTHOWORLD Inc.

Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: M&A